Biotechnology
Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China's NMPA
SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821) has been granted Breakthrough Therapy Designation (BTD) bythe Center for Drug Evaluation (CDE) of China's...
2024-08-12 22:00
1934
Actinogen announces achievement of clinically and statistically significant superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial
There was a clinically meaningful and persistent improvement depression measured by the key secondary endpoint of MADRS.[1] The primary endpoint of superiority to placebo in a cognitive "attention composite" of three Cogstate computerized tests was not met with large improvements seen in both Xan...
2024-08-12 20:30
1819
Milestone: Renal Nerve Mapping / Selective Renal Denervation (msRDN) System by SyMap Medical Ltd Approved for Treatment of Uncontrolled Hypertension in China
SUZHOU, China, Aug. 12, 2024 /PRNewswire/ -- On August 6, 2024, the msRDN System (SyMapCath I®/ SYMPIONEER S1®), developed by Suzhou/China-based SyMap Medical Ltd. (SyMap Medical), was approved by the National Medical Products Administration (NMPA) ofChina and granted a Class III Medical Devices ...
2024-08-12 13:55
1366
IASO Bio Receives U.S. FDA Approval of Investigational New Drug Application for Equecabtagene Autoleucel for Two New Autoimmune Disease Indications
SHANGHAI, NANJING, China and SAN JOSE, Calif., Aug. 12, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced that the investigation...
2024-08-12 13:52
1439
GenScript Biotech Reports First Half 2024 Results
Strong Revenue Growth and Strategic Advances Across Key Segments, Enhances Commitment to ESG and Sustainable Development * Impressive Financial Growth: The group reported a 43.5% increase in revenue, driven by a 156% boost in cell therapy revenue and a 75.4% rise in gross profit, showcasing s...
2024-08-09 23:19
3748
T-MAXIMUM PHARMACEUTICAL Announces Latest Clinical Advances in Allogeneic CAR-T Cell Therapy Breakthrough for Solid Tumors
Summary * T-Maximum Pharmaceutical develops allogeneic CAR-T therapies with a unique CRISPR/Cas9 Gene-Editing platform for solid tumors, provide a solution of two major pain points, GvHD and HvG, aiming to revolutionize cancer. * MT027, the product of target B7H3 received US FDA orphan drug d...
2024-08-08 20:00
2170
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
* Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispecific antibody platform WuXiBody™ * Collaboration is a three-year and potentially multi-TCR p...
2024-08-08 16:00
1782
WestGene to Advance Clinical Trials Following Dual IND Approvals for World's First EB Virus-Related mRNA Therapeutic Cancer Vaccine
CHENGDU, China, Aug. 7, 2024 /PRNewswire/ -- WestGene Biopharma is proud to announce that its mRNA therapeutic cancer vaccine, WGc-043, has received dual IND approvals fromChina's National Medical Products Administration (NMPA) and the US FDA. This unprecedented achievement marks the world's firs...
2024-08-08 10:59
1540
Concord Medical Regains Compliance with NYSE Minimum Price Requirement
BEIJING, Aug. 7, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it has received a letter from the New York Stoc...
2024-08-07 20:30
3246
Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States
TAIPEI, Aug. 7, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has signed a non-binding terms agreement with Eyenovia, Inc. ("Eyenovia", NASDAQ: EYEN), whereby the companies will co-develop Clobetasol Propionate Ophthalmic Suspensi...
2024-08-07 20:00
2072
Senhwa Biosciences receives US FDA Study May Proceed letter for the Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors
TAIPEI and SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced receipt of a "Study May Proceed" letter from the U.S. Food and Drug A...
2024-08-07 08:49
2319
Samsung Biologics joins the Pharmaceutical Supply Chain Initiative as Supplier Partner
* Samsung Biologics to embed PSCI principles into business practices for responsible value chain management * Supplier Partnership reaffirms company's commitment to decarbonize and build resilient supply chains INCHEON, South Korea, Aug. 6, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940....
2024-08-06 19:00
1836
First Patient Enrolled in the US Phase 2 Combination Therapy of Akeso's Ligufalimab with Azacitidine for Myelodysplastic Syndrome
HONG KONG, Aug. 6, 2024 /PRNewswire/ -- Akeso has announced the completion of the first patient enrollment in the US for the phase II clinical trial of its innovative CD47 monoclonal antibody, ligufalimab (AK117), in combination with azacitidine for patients with newly diagnosed higher-risk myelo...
2024-08-06 12:44
1654
OBiO Technology Congratulates on The First Clinical Gene Editing Therapy to Treat An Overseas Patient in China by CorrectSequence Therapeutics
SHANGHAI, Aug. 5, 2024 /PRNewswire/ -- Recently, CorrectSequence Therapeutics Co., Ltd. (Correctseq) announced a significant milestone in their base editing therapy CS-101 for transfusion-dependent β-thalassemia. Utilizing their pioneering transformer Base Editor (tBE), Correctseq has successfull...
2024-08-06 11:01
1768
META Pharmaceuticals announces FDA Grants Rare Pediatric Disease Designation to META-001-PH for the Treatment of Primary Hyperoxaluria
HONG KONG, Aug. 5, 2024 /PRNewswire/ -- META Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to its investigational new drug META-001-PH for the treatment of primary hyperoxaluria (PH).Primary hyperoxaluria is a...
2024-08-05 21:52
1894
Antennova Announces CD73 Small Molecule Inhibitor Accepted for Mini Oral Presentation at ESMO Congress 2024
BOSTON, Aug. 5, 2024 /PRNewswire/ -- Antennova, a clinical-stage biotech company focused on oncology today announced that the orally administered CD73 small molecule inhibitor ATN-037(also known as ATG-037) has been accepted for Mini Oral presentation at the 2024 European Society of Medical Oncol...
2024-08-05 20:00
1584
QBIOTICS WELCOMES STEPHEN DOYLE AS CHIEF EXECUTIVE OFFICER
* Stephen Doyle has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and Boehringer Ingelheim. He was most recently Chief Business Officer at Aslan Pharmaceuticals. * Mr Doyle brings extensive knowledg...
2024-08-05 19:00
1936
Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Ocular Surgery Relief and Recovery
TAIPEI, Aug. 5, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals (" Formosa", 6838.TWO) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), for exclusive rights inCanada to the commercialization of clobetasol propionate ophthalmi...
2024-08-05 16:30
1673
Novel Non-Covalent Hits Against GPX4 Identified Using the RiDYMO® Reinforced Dynamics Platform of DP Technology
Research on ferroptosis is gaining momentum, but the development of small molecule inhibitors faces numerous challenges BEIJING, Aug. 1, 2024 /PRNewswire/ -- Glutathione peroxidase 4 (GPX4) is recognized as a critical regulator of ferroptosis, playing a significant role in lipid and amino acid m...
2024-08-01 17:00
1826
MGI Tech Partners with UNALM and Inca Tops to Enhance Alpaca Fiber and Strengthen Peru's Textile Industry
* A genetic sequencing project involving 1,500 alpacas from Puno aims to refine the quality and fineness of their fiber. * The adoption of genomics in the alpaca industry offers many advantages, such as enhancing the quality of alpaca fiber and promoting the growth of thousands of producers i...
2024-08-01 15:47
1705
Week's Top Stories
Most Reposted
Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 305 media titles]
2024-11-20 13:29Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 303 media titles]
2024-11-21 10:30Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 299 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8683
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5536
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5116
Yingli Solar's Global Product Workshops Launched in Malaysia
2024-11-15 21:40
4753
